BridgeBio Pharma (BBIO)

Executive Summary

BridgeBio Pharma is a clinical-stage biotechnology company focused on developing transformative small-molecule medicines for genetic diseases and cancers with clear genetic origins. Utilizing an innovative hub-and-spoke organizational model, the company leverages centralized capabilities while maintaining autonomous teams for specific indications. With a market capitalization of approximately $13.4 billion and multiple Phase 3 programs, BridgeBio is well-positioned to address significant unmet medical needs. The company's most advanced asset, acoramidis (AG10), is a near-catalyst candidate for transthyretin amyloid cardiomyopathy (ATTR-CM), with a regulatory decision anticipated in the near term. Additionally, BridgeBio is advancing infigratinib for achondroplasia and BBP-631 for congenital adrenal hyperplasia, both of which have the potential to read out pivotal data in the coming months. The company's robust pipeline and strategic focus on genetically defined patient populations provide a strong foundation for near-term value creation.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on acoramidis for ATTR cardiomyopathy80% success
• Q4 2026Phase 3 top-line results for infigratinib in achondroplasia65% success
• Q3 2026Initiation of Phase 3 trial for BBP-631 in congenital adrenal hyperplasia70% success